WASHINGTON, D.C. — Israeli patients with hepatitis C virus infection
genotype 1 showed varied improvements after protease inhibitor-based
triple therapy, according to data presented at ICAAC 2014.
Researchers at the Soroka Medical Center in southern Israel treated 55 outpatients with hepatitis C virus (HCV) genotype 1 with telaprevir (n=39) or boceprevir (n=16) in combination with pegylated interferon and ribavirin between September 2011 and November 2013. Patients were followed for 6 months post-treatment.
“In our experience, protease inhibitor-based triple regimen for HCV
genotype 1, though more effective than previous dual treatment, is still
limited in effectiveness and holds major safety issues,” the
researchers wrote. “In light of the era where new, much more effective
and safe [direct-acting antivirals] begin to emerge, the triple therapy
in our view should be given mainly to patients with advanced disease
that cannot wait for the new drugs to be available and affordable.”